Navigation Links
International deal to screen potential cancer drugs using DNA 'barcodes'
Date:1/21/2014

An innovative screening technology that tags compounds with unique strands of DNA like barcodes will be used to assess up to a billion prototype drug molecules for anti-cancer activity, under a collaboration announced today (Tuesday) between The Institute of Cancer Research, London, Cancer Research Technology (CRT) and Denmark-based drug discovery company Nuevolution A/S.

Researchers will use Nuevolution's novel screening technology, Chemetics, to screen libraries of DNA-tagged compounds to identify those that act on a key protein in the stress response pathway, which has an important role in cancer cell survival and resistance to cancer treatments.

The collaboration will give scientists at The Institute of Cancer Research (ICR) access to data from screens of Nuevolution's proprietary library of small-molecule compounds, each of which is tagged with a unique strand of DNA marking it like a barcode. Up to a billion compounds will be assessed, with the successful hit compounds identifiable through their DNA tag. This state-of the-art screening technology allows potent drug leads to be identified quickly, accurately and from very large and complex compound mixtures.

The three-way deal between the ICR, Nuevolution and CRT, the commercial arm of Cancer Research UK, builds on a previous collaboration between CRT and Nuevolution, which aimed to identify drug leads that block the activity of several challenging cancer targets of therapeutic interest.

Under the new deal the Cancer Research UK Cancer Therapeutics Unit at the ICR and Nuevolution will collaborate to screen a key target within the stress response pathway using Nuevolution's Chemetics technology. Researchers from the Cancer Research UK Cancer Therapeutics Unit at the ICR will provide detailed insights and scientific expertise on the specific stress pathway target as well as their extensive experience in cancer drug discovery and development. In addition, they will use their cancer biology and molecular pharmacology expertise to validate prototype drug molecules identified by the Chemetics screening.

The parties have an option to co-develop promising compounds arising from this collaboration. The agreement is open-ended and allows for the screening of additional targets if the collaboration is successful.

Professor Paul Workman, Deputy Chief Executive of The Institute of Cancer Research, London, and Director of the Cancer Research UK Cancer Therapeutics Unit said: "The stress response pathway plays a key role in allowing cancer cells to survive and to develop drug resistance so it is increasingly being seen as an exciting source of future drug targets. But for some of these targets it is technically very challenging to identify prototype small molecule drugs. The new collaboration between the ICR, Cancer Research Technology and Nuevolution will allow us to screen very rapidly and efficiently for compounds that are able to bind to a key component of the stress response pathway that we have identified as especially important, and could help us to identify new drug candidates far more quickly than would otherwise be the case. By working in partnership we can accelerate the potential for patient benefit."

Dr Phil L'Huillier, Cancer Research Technology's director of business management, said: "Our role is to build global industry-academic partnerships to bring the best technologies and expertise together to develop new treatments for cancer patients ultimately saving more lives from the disease. This exciting international collaboration combines global expertise and resources to exploit the untapped biology of the stress response pathway.

"This work will accelerate the identification of potential new cancer drugs though an innovative approach to scan for DNA 'barcode' tags on promising new molecules extending the existing relationship between Nuevolution and CRT."

Thomas Franch, CSO, Nuevolution A/S said: "We are delighted to enter this project and to expand our present collaborations with ICR and CRT. The project will address a highly challenging target for which small molecule compounds is not easily identified using conventional screening methods. We hope to identify lead compounds using the Chemetics technology and look forward to moving this exciting project forward together with the world-leading team at ICR".


'/>"/>

Contact: Graham Shaw
Graham.Shaw@icr.ac.uk
44-020-715-35380
Institute of Cancer Research
Source:Eurekalert

Related biology news :

1. The International Society for Stem Cell Research announces its 2014 award recipients
2. Story of human regeneration wins international physics journalism prize
3. CROS NT Ltd Announces Acquisition of MDSL International Ltd.
4. EcoHealth Alliance and Bat Conservation International forge partnership to work on global bat conservation and public health issues
5. International team completes systematic, genomic study of cervical cancer
6. World e-waste map reveals national volumes, international flows
7. First International Bioenergy Conference brings together world-leading experts
8. International gene therapy trial for bubble boy disease shows promising early results
9. 20th International AIDS Conference (AIDS 2014) plenary speakers announced
10. Antibiotic resistance is a international issue that better education can address
11. NSF, with interagency and international partners, makes first round of grants to understand Arctic sustainability
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2017)... , Feb. 27, 2017   Strategic Cyber ... announced it has led a $3.5 million investment in  ... platform. Strategic Cyber Ventures is DC based and is ... Hank Thomas . Ron Gula , also ... Ventures, also participated in this series A round of ...
(Date:2/24/2017)...  EyeLock LLC, a leader of iris-based identity ... biometric solution on the latest Qualcomm® Snapdragon™ 835 ... World Congress 2017 (February 27 – March ... 3, Stand 3E10. The Snapdragon ... platform—a combination of hardware, software and biometrics ...
(Date:2/21/2017)... PORTLAND, Ore. , Feb. 22, 2017 ... Family of Companies (Avamere Health Services, Infinity Rehab, Signature ... research study that will apply the power of IBM ... living and health centers. By analyzing data streaming from ... insights into physical and environmental conditions, and obtain deeper ...
Breaking Biology News(10 mins):
(Date:2/28/2017)... ... February 28, 2017 , ... RoviSys, a ... today that it has joined the Cisco® Digital Solutions Integrator Program. As a ... hardware and software that addresses Industrial IT and Business IT in manufacturing environments. ...
(Date:2/28/2017)... ... , ... Over 8,000 recognized rare diseases afflict an estimated 350 million people ... March 7, DrugDev will gather international experts to share challenges and provide insight and ... Overcoming the Challenges of Rare Disease Clinical Trials, Date: March 7, 2017, Time: 10:00-11:00 ...
(Date:2/28/2017)... ... February 28, 2017 , ... GigaGen Inc ... millions-diverse immune repertoires, today announced a strategic partnership with Trianni, Inc. , ... express human antibodies. The partnership will use GigaGen technology to discover immuno-oncology antibody ...
(Date:2/28/2017)... and PHILADELPHIA , Feb. 28, 2017 ... held biopharmaceutical company focusing on debilitating diseases including rare ... announced that the company joins with the National Organization ... advocacy and support around the world in commemorating Rare ... unique challenges and needs of the millions of patients ...
Breaking Biology Technology: